# Krystal Biotech Inc. (KRYS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $358.24, market value $10.6 billion.

## Valuation
- **P/E (trailing): 44.8×** (5-yr avg 135.5×, 3-yr avg 135.5×). Krystal Biotech Inc. trades at 44.8× trailing earnings, well below its own five-year average of 135.5×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 38.1×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.30**. A PEG of 0.30 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 24.1×**. Each dollar of revenue is priced at 24.1×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 7.8×**. The shares trade at 7.8× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 2.4%** (5-yr avg -2.6%). Free cash flow equals 2.4% of the market value, above its five-year average of -2.6%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 2.2%**. The inverse of the P/E: 2.2% of the price is earned each year.

## Profitability
- **Operating margin: 44.9%**. 44.9% of revenue is left after running the business, an exceptional level.
- **Net margin: 52.6%**. 52.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 16.8%**. 16.8% on shareholders' equity is solid.
- **Return on assets: 18.1%**. Each dollar of assets produces 18.1% of profit.

## Growth
- **Revenue growth (1 yr): 33.9%**. Revenue grew 33.9% over the last year.
- **EPS growth (1 yr): 128.0%**. Earnings per share rose 128.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 9.95** (quick 9.95). Current assets cover the next year's liabilities 9.95 times.
- **Altman Z-score: 58.49**. A Z-score of 58.49 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Krystal Biotech Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 139.2%** (YTD 45.3%, 3-mo 19.0%). The shares are up 139.2% over twelve months including dividends.
- **From 52-week high: -6.4%** (162.0% above the low). Trading 6% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 55**. An RSI of 55 is neutral.
- **Beta (1 yr): 0.86** (volatility 39%). Beta of 0.86 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=KRYS · Page: https://foliofundamentals.com/stocks/krys

Not investment advice.